{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:15:47Z","timestamp":1785838547249,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-01952-1","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T08:29:44Z","timestamp":1737102584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation"],"prefix":"10.1186","volume":"26","author":[{"given":"Wanakorn","family":"Rattanawong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakit","family":"Anukoolwittaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akarin","family":"Hiransuthikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanakit","family":"Pongpitakmetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auranee","family":"Trisataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekh","family":"Thanprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"1952_CR1","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.ynpai.2022.100094","volume":"12","author":"W Rattanawong","year":"2022","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2022) Neurobiology of migraine progression. Neurobiol Pain 12:100094. https:\/\/doi.org\/10.1016\/j.ynpai.2022.100094","journal-title":"Neurobiol Pain"},{"key":"1952_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10194-020-01111-8","volume":"21","author":"M Torres-Ferr\u00fas","year":"2020","unstructured":"Torres-Ferr\u00fas M, Ursitti F, Alpuente A et al (2020) From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain 21:42. https:\/\/doi.org\/10.1186\/s10194-020-01111-8","journal-title":"J Headache Pain"},{"issue":"20181227","key":"1952_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.13459","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Greisman JD, Baigi K et al (2019) Migraine progression: a systematic review. Headache 59(20181227):306\u2013338. https:\/\/doi.org\/10.1111\/head.13459","journal-title":"Headache"},{"key":"1952_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s1474-4422(18)30322-3","volume":"17","author":"Global","year":"2018","unstructured":"Global (2018) Regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 17:954\u2013976. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"key":"1952_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13:361\u2013378. https:\/\/doi.org\/10.1007\/s10194-012-0460-7","journal-title":"J Headache Pain"},{"key":"1952_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0304-3959(03)00293-8","volume":"106","author":"AI Scher","year":"2003","unstructured":"Scher AI, Stewart WF, Ricci JA et al (2003) Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106:81\u201389. https:\/\/doi.org\/10.1016\/s0304-3959(03)00293-8","journal-title":"Pain"},{"key":"1952_CR7","doi-asserted-by":"publisher","first-page":"333102424124565","DOI":"10.1177\/03331024241245658","volume":"44","author":"W Rattanawong","year":"2024","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2024) Medication underuse headache. Cephalalgia 44:3331024241245658. https:\/\/doi.org\/10.1177\/03331024241245658","journal-title":"Cephalalgia"},{"key":"1952_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/head.13691","volume":"60","author":"HC Detke","year":"2020","unstructured":"Detke HC, Millen BA, Zhang Q et al (2020) Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache 60:348\u2013359. https:\/\/doi.org\/10.1111\/head.13691","journal-title":"Headache"},{"key":"1952_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013\u20092022 update. J Headache Pain 23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"1952_CR10","doi-asserted-by":"publisher","unstructured":"Charles AC, Digre KB, Goadsby PJ et al (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache  64:333\u2013341. 20240311. https:\/\/doi.org\/10.1111\/head.14692","DOI":"10.1111\/head.14692"},{"key":"1952_CR11","volume-title":"Guidelines for the diagnosis and treatment of migraine headache by the Headache Study Group under the Neurological Society of Thailand","author":"TTS Asawavichienjinda","year":"2022","unstructured":"Asawavichienjinda T, Thanprasertsuk S, Anukoolwittaya P (2022) Guidelines for the diagnosis and treatment of migraine headache by the Headache Study Group under the Neurological Society of Thailand. Thana Press Co., Ltd, Bangkok"},{"key":"1952_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-021-01222-w","volume":"22","author":"J Jedynak","year":"2021","unstructured":"Jedynak J, Eross E, Gendolla A et al (2021) Shift from high-frequency to low-frequency episodic migraine in patients treated with galcanezumab: results from two global randomized clinical trials. J Headache Pain 22:48. https:\/\/doi.org\/10.1186\/s10194-021-01222-w","journal-title":"J Headache Pain"},{"key":"1952_CR13","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1-211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1952_CR14","doi-asserted-by":"publisher","unstructured":"Lipton RB, Serrano D, Pavlovic JM et al (2014) Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study. Headache 54:830\u2013849. 20140417. https:\/\/doi.org\/10.1111\/head.12332","DOI":"10.1111\/head.12332"},{"key":"1952_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0333102416636055","volume":"37","author":"M Torres-Ferr\u00fas","year":"2017","unstructured":"Torres-Ferr\u00fas M, Quintana M, Fernandez-Morales J et al (2017) When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia 37:104\u201311320160711. https:\/\/doi.org\/10.1177\/0333102416636055","journal-title":"Cephalalgia"},{"key":"1952_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/0333102419895777","volume":"40","author":"M Guglielmetti","year":"2020","unstructured":"Guglielmetti M, Raggi A, Ornello R et al (2020) The clinical and public health implications and risks of widening the definition of chronic migraine. Cephalalgia 40:407\u2013410. https:\/\/doi.org\/10.1177\/0333102419895777","journal-title":"Cephalalgia"},{"key":"1952_CR17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1515\/sjpain-2021-0050","volume":"21","author":"S Di Antonio","year":"2021","unstructured":"Di Antonio S, Castaldo M, Ponzano M et al (2021) Disability, burden, and symptoms related to sensitization in migraine patients associate with headache frequency. Scand J Pain 21:766\u2013777. https:\/\/doi.org\/10.1515\/sjpain-2021-0050","journal-title":"Scand J Pain"},{"key":"1952_CR18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/head.13630","volume":"59","author":"J Ching","year":"2019","unstructured":"Ching J, Tinsley A, Rothrock J (2019) Prognosis following discontinuation of OnabotulinumA therapy in super-responding chronic migraine patients. Headache 59:1279\u2013128520190909. https:\/\/doi.org\/10.1111\/head.13630","journal-title":"Headache"},{"key":"1952_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1179\/1743132813y.0000000244","volume":"35","author":"SK Bhoi","year":"2013","unstructured":"Bhoi SK, Kalita J, Misra UK (2013) Is 6 months of migraine prophylaxis adequate? Neurol Res 35:1009\u20131014. https:\/\/doi.org\/10.1179\/1743132813y.0000000244","journal-title":"Neurol Res"},{"key":"1952_CR20","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s1474-4422(07)70272-7","volume":"6","author":"HC Diener","year":"2007","unstructured":"Diener HC, Agosti R, Allais G et al (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054\u20131062. https:\/\/doi.org\/10.1016\/s1474-4422(07)70272-7","journal-title":"Lancet Neurol"},{"issue":"20080318","key":"1952_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/ncpneuro0770","volume":"4","author":"TJ Schwedt","year":"2008","unstructured":"Schwedt TJ (2008) How long should patients with migraine continue to receive prophylactic topiramate? Nat Clin Pract Neurol 4(20080318):294\u2013295. https:\/\/doi.org\/10.1038\/ncpneuro0770","journal-title":"Nat Clin Pract Neurol"},{"key":"1952_CR22","doi-asserted-by":"publisher","first-page":"333102423118975","DOI":"10.1177\/03331024231189751","volume":"43","author":"M La Rocca","year":"2023","unstructured":"La Rocca M, Laporta A, Clemente L et al (2023) Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients. Cephalalgia 43:3331024231189751. https:\/\/doi.org\/10.1177\/03331024231189751","journal-title":"Cephalalgia"},{"key":"1952_CR23","doi-asserted-by":"publisher","first-page":"103531","DOI":"10.1016\/j.nicl.2023.103531","volume":"40","author":"E Szabo","year":"2023","unstructured":"Szabo E, Ashina S, Melo-Carrillo A et al (2023) Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: a prospective cohort study. Neuroimage Clin 40:103531. https:\/\/doi.org\/10.1016\/j.nicl.2023.103531","journal-title":"Neuroimage Clin"},{"key":"1952_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A et al (2022) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42:108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"key":"1952_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-022-01511-y","volume":"23","author":"M Ehrlich","year":"2022","unstructured":"Ehrlich M, Hentschke C, Sieder C et al (2022) Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study. J Headache Pain 23:141. https:\/\/doi.org\/10.1186\/s10194-022-01511-y","journal-title":"J Headache Pain"},{"key":"1952_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s10194-024-01859-3","volume":"25","author":"P Anukoolwittaya","year":"2024","unstructured":"Anukoolwittaya P, Hiransuthikul A, Pongpitakmetha T et al (2024) Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand. J Headache Pain 25:150. https:\/\/doi.org\/10.1186\/s10194-024-01859-3","journal-title":"J Headache Pain"},{"key":"1952_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S et al (2022) Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36:191\u201320220220211. https:\/\/doi.org\/10.1007\/s40263-021-00893-y","journal-title":"CNS Drugs"},{"key":"1952_CR28","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s10072-023-06683-2","volume":"44","author":"HC Lee","year":"2023","unstructured":"Lee HC, Cho S, Kim BK (2023) Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study. Neurol Sci 44:2455\u20132463. https:\/\/doi.org\/10.1007\/s10072-023-06683-2","journal-title":"Neurol Sci"},{"key":"1952_CR29","doi-asserted-by":"publisher","unstructured":"Caronna E, Gallardo VJ, Egeo G et al (2024) Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry 20240522. https:\/\/doi.org\/10.1136\/jnnp-2023-333295","DOI":"10.1136\/jnnp-2023-333295"},{"key":"1952_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-019-1024-x","volume":"20","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, Stauffer VL, Day KA et al (2019) Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain 20:75. https:\/\/doi.org\/10.1186\/s10194-019-1024-x","journal-title":"J Headache Pain"},{"key":"1952_CR31","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford JH, Jackson J, Milligan G et al (2017) A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache 57:1532\u20131544. https:\/\/doi.org\/10.1111\/head.13202","journal-title":"Headache"},{"key":"1952_CR32","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/j.1526-4610.2006.00577.x","volume":"46","author":"ME Bigal","year":"2006","unstructured":"Bigal ME, Lipton RB (2006) Modifiable risk factors for migraine progression. Headache 46:1334\u20131343. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00577.x","journal-title":"Headache"},{"key":"1952_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/0333102411430854","volume":"32","author":"AC Winter","year":"2012","unstructured":"Winter AC, Berger K, Buring JE et al (2012) Associations of socioeconomic status with migraine and non-migraine headache. Cephalalgia 32:159\u2013170. https:\/\/doi.org\/10.1177\/0333102411430854","journal-title":"Cephalalgia"},{"key":"1952_CR34","doi-asserted-by":"crossref","unstructured":"Vongvaivanich K, Yongprawat T, Jindawong N, Chansakul C. Test-Retest Reliability of the Thai Migraine Disability Assessment (Thai-MIDAS) Questionnaire in Thai Migraine Patients. Bangk Med J. 2018 Feb 20;14(1):10\u201310.","DOI":"10.31524\/bkkmedj.2018.02.003"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01952-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-01952-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01952-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T08:29:48Z","timestamp":1737102588000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-01952-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1952"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-01952-1","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board Research Ethics Committee (IRBREC) of the Faculty of Medicine, Chulalongkorn University, Bangkok, and KCMH in October 2023 (IRB number 706\/2023). The approval of retrieving retrospective data from electronic medical records (EMR) was made and informed consent was waived by IRBREC. All methods were carried out following relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Wanakorn Rattanawong receives speaker and advisory board honorarium from ZP therapeutics, DKSH Thailand, Pfizer Thailand, BL HUA, Viatris Thailand and Lundbeck; Prakit Anukoolwittaya receives speaker and advisory board honorarium from ZP therapeutics, DKSH Thailand, Pfizer Thailand, BL HUA, Akarin Hiransuthikul has no conflict of interest, Thanakit Pongpitakmetha receives speaker and advisory board honorarium from ZP therapeutics, Pfizer Thailand, and BL HUA, Auranee Trisataya is currently an employee at ZP therapeutics at the time of submission, Sekh Thanprasertsuk receives speaker and advisory board honorarium from ZP therapeutics, DKSH Thailand, Pfizer Thailand, BL HUA, Alan M. Rapoport serves as an advisor for AbbVie, Doctor Reddy\u2019s, Satsuma; he is on the Speakers Bureau of AbbVie, Doctor Reddy\u2019s and Teva Pharmaceutical Industries;\u00a0he is Editor-in-Chief of Neurology Reviews and on the Editorial Board of CNS Drugs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}